Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute.
Wilkes JD, Fidias P, Vaickus L, Perez RP. Wilkes JD, et al. Among authors: perez rp. Cancer. 1995 Oct 15;76(8):1377-87. doi: 10.1002/1097-0142(19951015)76:8<1377::aid-cncr2820760813>3.0.co;2-m. Cancer. 1995. PMID: 8620412 Review.
Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC. Perez RP, et al. Int J Cancer. 1991 May 10;48(2):265-9. doi: 10.1002/ijc.2910480219. Int J Cancer. 1991. PMID: 2019469
Soft tissue sarcomas in adults.
Karakousis CP, Perez RP. Karakousis CP, et al. Among authors: perez rp. CA Cancer J Clin. 1994 Jul-Aug;44(4):200-10. doi: 10.3322/canjclin.44.4.200. CA Cancer J Clin. 1994. PMID: 8019927 Review.
Mechanisms and modulation of resistance to chemotherapy in ovarian cancer.
Perez RP, Hamilton TC, Ozols RF, Young RC. Perez RP, et al. Cancer. 1993 Feb 15;71(4 Suppl):1571-80. doi: 10.1002/cncr.2820710424. Cancer. 1993. PMID: 8094321 Review.
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, et al. Schilder RJ, et al. Among authors: perez rp. Cancer Res. 1994 Feb 1;54(3):709-17. Cancer Res. 1994. PMID: 8306332 Clinical Trial.
Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity.
Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton TC, Godwin AK. Perez RP, et al. Cancer Res. 1993 Aug 15;53(16):3771-5. Cancer Res. 1993. PMID: 8339290
A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.
Perez RP, Godwin AK, Handel LM, Hamilton TC. Perez RP, et al. Eur J Cancer. 1993;29A(3):395-9. doi: 10.1016/0959-8049(93)90394-u. Eur J Cancer. 1993. PMID: 8398340
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors.
Creaven PJ, Raghavan D, Perez RP, Pendyala L, Berghorn EJ Jr, Loewen G, Meropol NJ. Creaven PJ, et al. Among authors: perez rp. Semin Oncol. 1996 Dec;23(6 Suppl 16):26-31. Semin Oncol. 1996. PMID: 9007117 Clinical Trial.
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA. Meropol NJ, et al. Among authors: perez rp. Clin Cancer Res. 1996 Apr;2(4):669-77. Clin Cancer Res. 1996. PMID: 9816217
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A. Perez RP, et al. Clin Cancer Res. 2006 Dec 1;12(23):7079-85. doi: 10.1158/1078-0432.CCR-06-0197. Clin Cancer Res. 2006. PMID: 17145831 Clinical Trial.
67 results
Jump to page
Feedback